



A Centralized Safety Repository



Cheryl Pace, Liverpool School of Tropical Medicine, UK



Drug Safety Repository (DSR)




Aims

- To collect and collate safety data from a variety of sources to identify the incidence of adverse reactions and look for new signals of potential harms.
- To develop a framework to allow this surveillance to extend to other drugs & diseases.




Pharmacovigilance systems

A C T



Pharmacovigilance systems

A C T




Drug Safety Repository



Key features

- Industry-standard web-based database for collating, recording and reporting events
- Restricted and secure access
- Integrated standardized dictionaries
- Flexible reporting tool

Case processing workflow



Case processing workflow



Overview

Case onset date: First received:

Case stop date: Last received:

Country: First contact type:

Report type: Medically confirmed: Yes No

Worldwide case identification number

Regulatory authority's number:

Other sender's case number:

Primary Source

Reporter last name: Reporter first name:

Reporter State / Province: Reporter country:

Telephone: Fax:

Reporter occupation:

Email:

Study name: Study Id:

Investigational medicinal product: Center Id:

From literature: Yes No

Citation:
#, Authors, Title of article, Journal Year, Vol:pg-pg.

Seriousness

Death: Yes No Death cause:

Life threatening: Yes No Hospitalization: Yes No

Disability: Yes No Congenital Anomaly: Yes No

Other medically important condition: Yes No

Other medically important condition details:

Core unlisted: Yes No Reporter causality:

- Manual data entry
- Electronic upload
- Duplicate checking

Source

- Case Overview
- Primary Sources
- Reporter Seriousness

Events

- Adverse Events
- Device Incident

Patient

- Patient
- Medical History
- Drug Therapies
- Parents
- Pregnancy
- Supplemental Data
- Vaccine History

Product

- Medicinal Product**
 - Suspect Drugs
 - Concomitant Drugs
- Medical Device**
 - Suspect Devices
 - Concomitant Devices
- Vaccine**
 - Suspect Vaccines
 - Concomitant Vaccines
 - Vaccine Administration

Relatedness

- Medicinal Products
- Devices
- Vaccines

Supplemental

- Lab Data
- Attachments
- Notes
- Narratives
- Company Seriousness

Overview

Case onset date: First received:

Case stop date: Last received:

Country: First contact type:

Report type: **Medically confirmed:** Yes No

Worldwide case identification number:

Regulatory authority's number:

Other sender's case number:

Primary Source

Reporter last name: Reporter first name:

Reporter State / Province: Reporter country:

Telephone: Fax:

Reporter occupation:

Email:

Study name: Study Id:

Investigational medicinal product: Center Id:

From literature: Yes No

Citation:
#, Authors, Title of article, Journal Year; Vol:pg-pg.

Seriousness

Death: Yes No Death cause:

Life threatening: Yes No Hospitalization: Yes No

Disability: Yes No Congenital Anomaly: Yes No


Other medically important condition: Yes No

Other medically important condition details:

Core unlisted: Yes No Reporter causality:

- Source**
 - Case Overview
 - Primary Sources
 - Reporter Seriousness
- Events**
 - Adverse Events
 - Device Incident
- Patient**
 - Patient
 - Medical History
 - Drug Therapies
 - Parents
 - Pregnancy
 - Supplemental Data
 - Vaccine History
- Product**
 - Medicinal Product**
 - Suspect Drugs
 - Concomitant Drugs
 - Medical Device**
 - Suspect Devices
 - Concomitant Devices
 - Vaccine**
 - Suspect Vaccines
 - Concomitant Vaccines
 - Vaccine Administration
- Relatedness**
 - Medicinal Products
 - Devices
 - Vaccines
- Supplemental**
 - Lab Data
 - Attachments
 - Notes
 - Narratives
 - Company Seriousness

Case processing workflow



WHO Drug Dictionary

MedDRA - the Medical Dictionary for Regulatory Affairs



View Full Coding -- Webpage Dialog

https://www.lstm-pv.co.uk/EtraceProd/pf.aspx/ViewContainer?name=ClintraceCodingFullCodingViewCt

View Full Coding [?]

Previous

Coded with: WHODrugC 0614

Verbatim:

Modified Verbatim:

Code	Term	Term2	Level
	Riamet	Artemether,Lumefantrine	Generic Ingredients
	Coartem		Tradename
	Not specified		Manufacturer
	Coartem	[xmitem][cos]Unspecified[/cos][cmp]None[/cmp][cmp_cntry]Unspecified[/cmp_cntry][ma_cntry]Unspecified[/ma_cntry][prt]Medicinal product[/prt][prg]None[/prg][prods][prod][form]Unspecified[/form][ings][ing][name]Artemether[/name][qty]/[qty][unit]unspec[/unit]/[ing][ing][name]Lumefantrine[/name][qty]/[qty][unit]unspec[/unit]/[ing]/[ings]/[prod]/[prods]/[xmitem]	Name w/Specifier CFormat Info

View Full Coding -- Webpage Dialog

https://www.lstm-pv.co.uk/EtraceProd/pf.aspx/ViewContainer?name=ClintraceCodingFullCodingViewCt

View Full Coding [?]

Previous

Coded with: MedDRA 17.0

Verbatim:

Modified Verbatim: Is Primary Path:

Code	Term	Term2	Level
	Respiratory, thoracic and mediastinal disorders		System Organ Class
	Lower respiratory tract disorders (excl obstruction and infection)		High Level Group Term
	Lower respiratory tract inflammatory and immunologic conditions		High Level Term
	Pneumonia aspiration		Preferred Term
	Aspiration pneumonia		Low Level Term

- Integrated into database
- Automated & manual coding
- Drugs
- Diseases
- Events
- Investigations

Case processing workflow



- Data entry checks
- Coding checks
- Missing data

Case processing workflow





- Regulatory & ad hoc reports
- Status reports
- Case lists
- Automated & manual reports

Reporting – summary tabulations



System Organ Class (MedDRA)	Drug 1	Drug 2	Drug 3	Summary
n	3446	2931	1288	10792
Blood and lymphatic system disorders	30 (0.9%)	0 (0.0%)	0 (0.0%)	30 (0.4%)
Cardiac disorders	1 (0.0%)	2 (0.1%)	0 (0.0%)	3 (0.0%)
Eye disorders	0 (0.0%)	3 (0.1%)	3 (0.2%)	6 (0.1%)
Gastrointestinal disorders	12 (0.3%)	155 (5.3%)	32 (2.5%)	199 (2.6%)
General disorders and administration site conditions	7 (0.2%)	61 (2.1%)	3 (0.2%)	71 (0.9%)
Hepatobiliary disorders	0 (0.0%)	3 (0.1%)	0 (0.0%)	3 (0.0%)
Infections and infestations	227 (6.6%)	24 (0.8%)	10 (0.8%)	261 (3.4%)
Injury, poisoning and procedural complications	5 (0.1%)	0 (0.0%)	1 (0.1%)	6 (0.1%)
Metabolism and nutrition disorders	6 (0.2%)	3 (0.1%)	2 (0.2%)	11 (0.1%)
Musculoskeletal and connective tissue disorders	0 (0.0%)	1 (0.0%)	2 (0.2%)	3 (0.0%)
Nervous system disorders	39 (1.1%)	54 (1.8%)	15 (1.2%)	108 (1.4%)
Psychiatric disorders	0 (0.0%)	5 (0.2%)	1 (0.1%)	6 (0.1%)
Renal and urinary disorders	0 (0.0%)	2 (0.1%)	0 (0.0%)	2 (0.0%)
Reproductive system and breast disorders	0 (0.0%)	0 (0.0%)	2 (0.2%)	2 (0.0%)
Respiratory, thoracic and mediastinal disorders	4 (0.1%)	16 (0.5%)	0 (0.0%)	20 (0.3%)
Skin and subcutaneous tissue disorders	1 (0.0%)	18 (0.6%)	2 (0.2%)	21 (0.3%)
Vascular disorders	0 (0.0%)	0 (0.0%)	2 (0.2%)	2 (0.0%)
Summary	333 (9.7%)	352 (12.0%)	80 (6.2%)	765 (10.0%)

Reporting - graphs



Reporting - line listings



Serious events

System Organ Class (MedDRA)	Sex	Age Group	Event as reported	Preferred term (MedDRA)	Intensity	First dose to onset	Outcome
Blood and lymphatic system disorders	FEMALE	Adult	Anaemia	Anaemia	Life threatening	12 weeks 1 day	Recovered
Congenital, familial and genetic disorders	MALE	Neonate	Cleft palate and lip	Cleft lip and palate	Moderate	NA	Not Recovered
Renal and urinary disorders	FEMALE	Infant	Acute renal failure	Renal failure acute	NA	18 weeks 5 days	Fatal
	FEMALE	Adult	Unable to pass urine	Dysuria	SEVERE	5 days	Recovered

Non-serious events

System Organ Class (MedDRA)	Sex	Pt Id	Event as reported	Preferred term (MedDRA)	Intensity	Onset	Outcome
Gastrointestinal disorders	MALE	Child	Diarrhoea	Diarrhoea	Moderate	1 day	Recovering
	FEMALE	Adult	Vomiting	Vomiting	Mild	30 minutes	Recovered
Nervous system disorders	FEMALE	Adult	Headache	Headache	Moderate	1 day	Recovered
	FEMALE	Adult	Dizziness	Dizziness	Mild	60 minutes	Recovered
Musculoskeletal and CT disorders	MALE	Adult	Muscle pains	Myalgia	MILD	2 days	Recovered
Renal and urinary disorders	FEMALE	Child	Dark urine	Chromaturia	MILD	4 days	Recovering

Current status



- Validated
- Contains >3000 case reports predominantly from ACTc and MiPc
- Reporting to DSMBs, ethics committees, manufacturers tried and tested
- Providing PV services to other malaria studies
- Standardization and pooled analysis remains a challenge
- Potential future collaborations – other investigators & Consortia, other pooled data initiatives (e.g. WWARN).....



Thank you for joining us!

Recording will be shared. Please ensure you are on our mailing list:

www.actconsortium.org/newsletter

For any questions or comments, contact

debora.miranda@lshtm.ac.uk

